–
Leveraging the Company’s proprietary S1S3 bicistronic expression platform, M041 is co-expressed human NAGLU and S1S3, resulting in NAGLU
M6P –
–
With increased efficiency to phosphorylate lysosomal enzymes, M041 is a potential novel recombinant enzyme therapy for Sanfilippo B syndrome –
ST. LOUIS, MO, USA I July 28, 2021 IM6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced pre-clinical proof-of-concept data on M041 in a poster presentation by Patricia Dickson, M.D., Centennial Professor of Pediatrics and Chief, Division of Genetics and Genomic Medicine, Washington University of St. Louis, titled “